Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Anbio Biotechnology Class A ( (NNNN) ) is now available.
On December 30, 2025, Anbio Biotechnology reported unaudited financial results for the six months ended June 30, 2025, showing revenue of about $4.6 million, down from roughly $5.8 million a year earlier, as the company prioritized higher‑margin business and adjusted its product mix. Despite the top-line decline, gross profit rose to approximately $4.2 million with gross margin expanding sharply to about 92.3% from 66.9%, and net income increased to around $3.8 million versus $3.6 million in the prior‑year period, reflecting a strategic focus on profitability and higher‑margin IVD products. Operating income edged down slightly to about $3.4 million, while selling, general and administrative expenses climbed due to costs tied to its February 2025 Nasdaq listing and related compliance, and R&D spending remained steady as Anbio continued to develop new diagnostic products and assays. As of June 30, 2025, the company reported cash and cash equivalents of around $5.3 million, working capital of roughly $27.5 million, and total assets of about $27.7 million against minimal liabilities, underpinned by IPO proceeds and operating cash flow. Operationally, Anbio continued its strategic shift beyond pandemic-related testing, with approximately 94.6% of commercial IVD revenue during the period coming from non‑COVID products, reinforcing its positioning as a diversified global diagnostics provider focused on higher-margin, non‑COVID solutions.
More about Anbio Biotechnology Class A
Anbio Biotechnology is a medical device company specializing in in vitro diagnostic (IVD) solutions, offering a broad portfolio of diagnostic assays across six biomarker detection platforms for point-of-care, laboratory and over-the-counter use. With a strong global presence in the EU, APAC and the Americas, its CE‑marked products target biomarkers associated with infectious diseases, cancer, cardiovascular and endocrine disorders, inflammation, renal disease, drug abuse, pharmacogenomics and diabetes, and are designed to work with multiple sample types including blood, feces, urine and saliva, supporting personalized and decentralized diagnostic testing.
Average Trading Volume: 49,091
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.66B
For an in-depth examination of NNNN stock, go to TipRanks’ Overview page.